Exact Science Lab’s OncoExTra Therapy Chosen for ComboMATCH Clinical Trials by National Cancer Institute

Published on: 

Therapy selection test to analyze tumor samples for participants in precision medicine initiative.

Exact Sciences Corp. revealed that it has been selected by the National Cancer Institute (NCI) to contribute to the ComboMATCH clinical trials, one of its precision medicine initiatives. Using its Phoenix, Ariz. ComboMATCH-designated lab, Exact Sciences will rely on its OncoExTra™ test to analyze tumor tissue and paired normal blood samples from patient participants and uncover the specific abnormalities in a patient's tumor that may be most effective to treat.


"Most cancers do not have a single underlying cause or driver; so, no single targeted therapy is likely to work, especially in the long-term given the challenge of drug resistance," said James M. Ford, MD, Stanford University School of Medicine, co-leader of ComboMATCH, leader of the coordination effort by the ECOG-ACRIN Cancer Research Group, in a company press release. "Mounting evidence demonstrates the important role of genomic profiling to guide therapeutic choices when treating cancer, and offers the potential for greater patient benefit, paving the way to new frontiers in cancer treatment."

Reference: Exact Sciences Lab and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical Trials. PR Newswire. August 30, 2023. Accessed September 5, 2023. https://www.prnewswire.com/news-releases/exact-sciences-lab-and-oncoextra-test-selected-by-national-cancer-institute-for-combomatch-clinical-trials-301912803.html